Related Experiment Video
Updated: May 8, 2026
08:53
Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells
Published on: May 16, 2017
C9ORF72 mutations in neurodegenerative diseases
Ying Liu1, Jin-Tai Yu, Yu Zong
1Department of Neurology, Qingdao Municipal Hospital, Dalian Medical University, Dalian, China.
Molecular Neurobiology
|August 13, 2013
Summary
Expansion of the C9ORF72 gene hexanucleotide repeat causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Understanding these mutations offers new therapeutic targets for related neurological diseases.
Area of Science:
- Genetics
- Neuroscience
- Molecular Biology
Background:
- A GGGGCC hexanucleotide repeat expansion in the C9ORF72 gene is a major cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
- C9ORF72 protein is expressed in various tissues, including the brain, and its mutations are linked to diverse neurological disorders.
Purpose of the Study:
- To review the characteristics of the C9ORF72 gene and its expansion mutations.
- To discuss the clinical manifestations and pathological mechanisms of C9ORF72-related neurological diseases.
- To identify potential therapeutic targets for C9ORF72 mutation-related disorders.
Main Methods:
- Literature review of C9ORF72 gene, expansion mutations, and associated neurological diseases.
- Analysis of clinical features and pathological mechanisms.
- Discussion of current knowledge gaps and future research directions.
Main Results:
- C9ORF72 mutations are associated with a broad spectrum of neurological conditions, including ALS, FTD, and others.
- Mutations can affect C9ORF72 protein levels and RNA foci formation, impacting cellular function.
- The diverse clinical presentations highlight the complexity of C9ORF72-related pathologies.
Conclusions:
- Understanding C9ORF72 mutations provides crucial insights into the pathogenesis of ALS and FTD.
- Further research into the molecular mechanisms is essential for developing effective therapies.
- Targeting C9ORF72 pathways offers promising avenues for treating these devastating neurological diseases.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...